Skip to main content

Table 1 Alzheimer’s disease-related mechanisms of action of repurposed agents in the pipeline (ClinicalTrials.gov as of February 27, 2020)

From: Repurposed agents in the Alzheimer’s disease drug development pipeline

Approved therapeutic area Disease-modifying therapies Cognitive enhancers Behavioral symptoms Behavioral + cognitive symptoms Total # of agents (%)
Hematologic-oncologic 10 10 (20.0)
Cardiovascular 7 1 1 9 (18.0)
Psychiatric 1 1 4 1 7 (14.0)
Antidiabetic 6 6 (12.0)
Neurologic 3 2 5 (10.0)
Infectious disease 3 3 (6.0)
Anti-inflammatory 2 2 (4.0)
Genetics 1 1 (2.0)
Cannabinoid 1 1 (2.0)
Hormonal 1 1 (2.0)
Immunologic 1 1 (2.0)
Alkaloid 1 1 (2.0)
Pulmonary 1 1 (2.0)
Nutraceutical 1 1 (2.0)
Vitamin 1 1 (2.0)
TOTAL 38 3 8 1 50 (100.0)